NCT00856375 - NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

July 31, 2014

Study Completion Date

December 31, 2014

Conditions

Colorectal Cancer

Interventions

DRUG

NKTR-102

IV every 3 weeks

DRUG

irinotecan

IV every 3 weeks

Trial Locations (24)

2020

Investigator Site - Antwerp, Antwerp

14215

Investigator Site - Buffalo, Buffalo

28034

Investigator Site - Madrid, Madrid

29223

Investigator Site - Celle, Celle

37909

Investigator Site - Knoxville, Knoxville

40202

Investigator Site - Louisville, Louisville

48201

Investigator Site - Detroit, Detroit

Investigator Site - Karlsruhe, Karlsruhe

62801

Investigator Site - Centralia, Centralia

85381

Investigator Site - Peoria, Peoria

90033

Investigator Site - Los Angeles, Los Angeles

91505

Investigator Site - Burbank, Burbank

94589

Investigator Site - Vallejo, Vallejo

380009

Investigator Site - Ahmedabad, Ahmedabad

500004

Investigator Site - Hyderabad, Hyderabad

560054

Investigator Site - Bangalore, Bangalore

560078

Investigator Site - Bangalore, Bangalore

682041

Investigator Site - Kochi, Kochi

700026

Investigator Site - Kolkata, Kolkata

700053

Investigator Site - Kolkata, Kolkata

91-98-50986003

Investigator Site - Mumbai, Mumbai

34-966-616250

Investigator Site - Elche, Elche

AB25 2ZN

Investigator Site - Aberdeen, Aberdeen

MD20 4BX

Investigator Site - Manchester, Manchester